Hanall Biopharma Co., Ltd.

Daewoong Pharmaceutical Co., Ltd.

Immunomet Therapeutics Inc.

Yeon Jung Song

Sung Wuk Kim

Eun Sun Kim

Seung Kook Park

Jae Kap Jeong

Hyea Kyung Ahn

Hae-Young Yong

Dongok Shin

Min Sun Kim

Ha Na Kim

Sung Soo Jun

Song Young Kim

Tae Hyoung Yoo

Joon Seok Park

Ji Sun Lee

Sun Young Kim

Hye Jin Heo

Hong Bum Lee

Mi Ryeong Han

Min Jeong Kim

Kyung A Yu

Ji Ae Kook

Yun Soo Yoon

Eun Kyoung Shin

Soon Im Lee

Hung Keun Lee

Kang-Pil Kim

Jeong Haing Heo

Min Jae Shin

Kook Hwan Oh

Kyung Don Ju

Hye Soun Eum

Shin Dongok

The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.

Antibody binding to FCRN for treating autoimmune diseases

Antibody binding to FcRn for treating autoimmune diseases

The present invention relates to a human antibody specific for FcRn that is a receptor with a high affinity for IgG, a production method thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune disease using the same. The FcRn-specific antibody according to the present invention can bind to FcRn non-competitively with IgG or the like to reduce serum auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.

FcRn-specific human antibody and composition for treatment of autoimmune diseases

The present invention provides a novel use of N1-cyclic amine-N5-substituted biguanide derivatives for preparing a medicine for preventing or treating fibrosis. The N1-cyclic amine-N5-substituted biguanide derivatives according to the present invention are capable of effectively inhibiting fibrosis by effectively suppressing the EMT.

Pharmaceutical composition comprising N1-cyclic amine-N5-substituted biguanide derivatives as an ingredient for preventing or treating fibrosis

The present invention relates to new uses of modified human tumor necrosis factor receptor-1 (TNFRI) polypeptide, and more particularly, to uses thereof for prevention and treatment of dry eye syndrome. The modified TNFRI or modified TNFRI fragment of the present invention has excellent TNF&#x3b1; neutralizing activity, and inhibits TNF&#x3b1; activity on the ocular surface of the patient to suppress inflammation induction effects related to dry eye. Therefore, the modified TNFRI or modified TNFRI fragment of the present invention exhibits remarkable effects in the prevention and treatment of dry eye syndrome, and thus can be very useful in the prevention and treatment of dry eye syndrome.

Uses of modified human tumor necrosis factor receptor-1 polypeptide

The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide to be coupled to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof. The modified human tumor necrosis factor receptor-1 polypeptide or the fragment thereof according to the present invention exhibit improved resistance against in vivo protease activity, and thus exhibit improved bioavailability and an improved absorption rate.

Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same

The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide which is capable of binding to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof. The modified human tumor necrosis factor receptor-1 polypeptide or the fragment thereof according to the present invention exhibit improved binding affinity to the tumor necrosis factor.

Modified human tumor necrosis factor receptor-I polypeptide or fragment thereof, and method for preparing same

Provided is a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof that binds to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor receptor-1 polypeptide or fragment exhibits improved ability to bind tumor necrosis factor and resistance to proteases.

Disclosed herein are antifungal triazole derivatives or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition comprising the same. The triazole derivatives of Chemical Formula 1 or pharmaceutically acceptable salts thereof according to the present invention have excellent inhibitory activity against a broad spectrum of fungi, in addition to being safe to the body, and thus are very useful in the treatment and prevention of fungal infection.

Antifungal triazole derivatives

Growing community of inventors

Gyeonggi-do, South Korea

Yeon Jung Song